不同剂量辛伐他汀早期干预对急性冠状动脉综合征患者血清C反应蛋白的影响

目的观察不同剂量辛伐他汀早期干预对急性冠状动脉综合征(ACS)患者血清高敏C反应蛋白(hs-CRP)水平的影响及调脂作用与安全性。方法75例ACS患者随机分为三组,A组为优化药物治疗,B组为优化药物治疗加辛伐他汀20mg/d,C组为优化药物治疗加辛伐他汀40mg/d,均治疗4周,健康对照组不予治疗。分别于用药前及疗程结束后查hs-CRP及血脂水平,同时观察用药安全性。结果(1)ACS患者hs-CRP、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)含量显著高于健康对照组(P<0.01)。(2)辛伐他汀20mg与40mg治疗4周后,均能显著降低hs-CRP、TC、LDL-C及TG水平(P均<0.01),其中40mg剂量组的疗效明显优于20mg剂量组。结论ACS患者hs-CRP显著升高,存在明显的炎症反应,早期大剂量辛伐他汀调脂干预,能安全更有效地抑制此类炎症反应及脂质过氧化损伤,且呈剂量依赖性。

Effect of different dose of simvastatin early treatment on serum C-reactive protein in patients with acute coronary syndrome

Objective To observe the effect on serum hs-CRP and the regulation of the lipid level and the security of different dose of simvastatin early interfere in patients with acute coronary syndrome.Methods 75 patients with ACS were randomly divided into three groups.Optimized drug was used in group A and combined simvastatin 20mg daily in group B and combined simvastatin 40mg daily in group C.All were received treatment for 4 weeks.While the healthy patients in the control group were not received any therapy.The level of hs-CRP and serum lipid were measured both before and after treatment,And the medicine security was observed at the same time.Results(1)The values of hs-CRP,TC,LDL-C,TG in patients with ACS were significantly higher than in the controngroup(P<0.01).(2)after 4weeks treatment,the two groups of 20mg daily and 40mg daily of simvastatin decreased significanly the levels of hs-CRP,TC,LDL-C,TG(P<(0.0l),)And the efficacy of group C was better than group B.Conclusion Significant increase in the level of hs-CRP and obvious inflammation are observed in patients with ACS.Early high-dose of simvastatin interference with lipid regulation can be inhibited the inflammatory response and lipid peroxidation,and decreased the rate of ACS,appearing on dose relation.